Evidence map›Paper›PMID 39006170›Full record

ArticleNature reviews. Methods primers2024

Top-down proteomics.

David S Roberts, Joseph A Loo, Yury O Tsybin, Xiaowen Liu, Si Wu, Julia Chamot-Rooke, Jeffrey N Agar, Ljiljana Paša-Tolić, Lloyd M Smith, Ying Ge

Abstract read
In one paragraph

Article in Nature reviews. Methods primers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 88 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
88citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

88 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. A Draft Map of E. coli Proteoforms.Analytical chemistry · 2026
    Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Deep Proteoform Sequencing with Top-Down Direct Mass Technology.bioRxiv : the preprint server for biology · 2026
    Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

28 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

David S RobertsDepartment of Chemistry, Stanford University, Stanford, CA, USA.ORCID 0000-0002-0478-4987
Joseph A LooDepartment of Chemistry and Biochemistry, Department of Biological Chemistry, University of California - Los Angeles, Los Angeles, CA, USA.ORCID 0000-0001-9989-1437
Yury O TsybinSpectroswiss, Lausanne, Switzerland.ORCID 0000-0001-7533-0774
Xiaowen LiuDeming Department of Medicine, School of Medicine, Tulane University, New Orleans, LA, USA.ORCID 0000-0003-4139-1127
Si WuDepartment of Chemistry and Biochemistry, The University of Alabama, Tuscaloosa, AL, USA.ORCID 0000-0002-6346-7359
Julia Chamot-RookeInstitut Pasteur, Université Paris Cité, CNRS UAR 2024, Paris, France.
Jeffrey N AgarDepartments of Chemistry and Chemical Biology and Pharmaceutical Sciences, Northeastern University, Boston, MA, USA.
Ljiljana Paša-TolićEnvironmental and Molecular Sciences Division, Pacific Northwest National Laboratory, Richland, WA, USA.ORCID 0000-0001-9853-5457
Lloyd M SmithDepartment of Chemistry, University of Wisconsin, Madison, WI, USA.ORCID 0000-0002-6652-8639
Ying GeDepartment of Chemistry, University of Wisconsin, Madison, WI, USA.

Funding

Translation of immunologic technologies from basic research into pre-clinical nonU19AI062629 · NIAID · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI COGGESHALL, KENNETH MARK · 2004 to 2023
$56.2M
Revealing Proteoforms: The Primary Effectors of Biological FunctionR35GM126914 · NIGMS · UNIVERSITY OF WISCONSIN-MADISON · PI Lloyd M Smith · 2018 to 2026
$6.2M
Deciphering Myofilament Modifications in Ischemic CardiomyopathyR01HL109810 · NHLBI · UNIVERSITY OF WISCONSIN-MADISON · PI GE, YING · 2013 to 2024
$3.5M
Top Down Proteomics Of Myofilaments In Heart FailureR01HL096971 · NHLBI · UNIVERSITY OF WISCONSIN-MADISON · PI GE, YING · 2011 to 2021
$3.3M
Computational tools for top down mass spectrometry based proteoform identification and proteogenomicsR01GM118470 · NIGMS · TULANE UNIVERSITY OF LOUISIANA · PI Xiaowen Liu · 2016 to 2026
$2.7M
Enabling Top-Down Proteomics through Materials Chemistry and NanotechnologyR01GM117058 · NIGMS · UNIVERSITY OF WISCONSIN-MADISON · PI GE, YING, JIN, SONG · 2015 to 2023
$2.7M
Quantitative Analysis of Serum Autoantibody Repertories in Systemic Lupus ErythematosusR01AI141625 · NIAID · UNIVERSITY OF OKLAHOMA · PI SINGH, SHANTERI, SMITH, KENNETH MICHAEL · 2019 to 2023
$2.1M
Quantitative top-down proteomics of human colorectal cancer cells and tumorsR01CA247863 · NCI · MICHIGAN STATE UNIVERSITY · PI HUMMON, AMANDA B., LIU, XIAOWEN · 2021 to 2025
$1.9M
Advancing Mass Spectrometry Analyses of Proteins, Assemblies, and ProteoformsR35GM145286 · NIGMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Joseph A Loo · 2022 to 2026
$1.9M
MASH Explorer, a Comprehensive Software Environment for Top-Down ProteomicsR01GM125085 · NIGMS · UNIVERSITY OF WISCONSIN-MADISON · PI GE, YING · 2018 to 2021
$1.2M
Spatially resolved characterization of proteoforms for functional proteomicsUH3CA256959 · NCI · BATTELLE PACIFIC NORTHWEST LABORATORIES · PI PASA-TOLIC, LJILJANA · 2022 to 2023
$1.0M
NCI NIH HHS R01 CA247863NCI NIH HHS UH3 CA256959NHLBI NIH HHS R01 HL096971NHLBI NIH HHS R01 HL109810NIAID NIH HHS R01 AI141625NIAID NIH HHS U19 AI062629NIGMS NIH HHS R01 GM117058NIGMS NIH HHS R01 GM118470NIGMS NIH HHS R01 GM125085NIGMS NIH HHS R35 GM126914NIGMS NIH HHS R35 GM145286
6 · The paper itself

Abstract

Proteoforms, which arise from post-translational modifications, genetic polymorphisms and RNA splice variants, play a pivotal role as drivers in biology. Understanding proteoforms is essential to unravel the intricacies of biological systems and bridge the gap between genotypes and phenotypes. By analysing whole proteins without digestion, top-down proteomics (TDP) provides a holistic view of the proteome and can decipher protein function, uncover disease mechanisms and advance precision medicine. This Primer explores TDP, including the underlying principles, recent advances and an outlook on the future. The experimental section discusses instrumentation, sample preparation, intact protein separation, tandem mass spectrometry techniques and data collection. The results section looks at how to decipher raw data, visualize intact protein spectra and unravel data analysis. Additionally, proteoform identification, characterization and quantification are summarized, alongside approaches for statistical analysis. Various applications are described, including the human proteoform project and biomedical, biopharmaceutical and clinical sciences. These are complemented by discussions on measurement reproducibility, limitations and a forward-looking perspective that outlines areas where the field can advance, including potential future applications.

Identifiers

PMID39006170
PMCPMC11242913

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.